Feedback
Tramadol and Metabolites, Serum or Plasma, Quantitative
2002764
Ordering Recommendation
 
Mnemonic
TRAMAD SP
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Tue, Thu
Reported
1-6 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).  
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles.  
Remarks
Submit With Order
Please indicate in the supplied fields:
1.  Dose - List drug amount and include the units of measure
2.  Route - List the route of administration (IV, oral, etc.)
3.  Dose Frequency - Indicate how often the dose is administered (per day, per week, as needed, etc.)
4.  Type of Draw - Indicate the type of blood draw (Peak, Trough, Random, etc.)  
Stability
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years  
Reference Interval
Effective August 17, 2015
 
Drugs Covered Cutoff Concentrations
Tramadol 50 ng/mL
N-​desmethyltramadol (qualitative only) 100 ng/mL
O-​desmethyltramadol (qualitative only) 100 ng/mL
Interpretive Data
Interpretive Data:Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive cutoff:

Tramadol: 50 ng/mL
n-desmethyltramadol : 100 ng/mL
o-desmethyltramadol: 100 ng/mL

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug may indicate use of parent drug during the prior week.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
80373; (Alt code: 80299)
Components
Component Test Code*Component Chart NameLOINC
2002741Tramadol, S/P, Quant12437-0
2002765N-desmethyltramadol, S/P, Qual 
2002768O-desmethyltramadol, S/P, Qual 
2011585Tramadol Dose 
2011586Tramadol Dose Frequency 
2011587Tramadol Route 
2011588Tramadol Type of Draw 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Topalgic
  • Tramadol
  • tramadol blood level
  • Tramal
  • Ultracet (Tramadol Component)
  • Ultram
  • ultram blood level
  • Zamudol